Paris-based Sanofi-Aventis SA's buyout of Genzyme includes by far the biggest CVR dollars this year – about $3.8 billion, most of that hinging on the success of multiple sclerosis drug alemtuzumab

for $6.6 billion, but is only the second largest deal of 2011, after Sanofi-aventis's takeover of Genzyme Corp. (See BioWorld Today, Sept. 29, 2009, and Feb. 18, 2011.)

entered into a research agreement with Sanofi Pasteur, of Lyon, France, the vaccines division of Sanofi-Aventis Group, and EnGen Bio Inc., of Redwood City, Calif

Sanofi-Aventis SA (Paris) 8/31 4/11 $21.2B Sanofi-Aventis bought Genzyme for $21.2B Kinaxo Biotechnologies GmbH (Munich, Germany) Evotec AG (Hamburg, Germany) 2/10 4/19 €12 ($16.4) Evotec acquired all shares of Kinaxo with cash and 2.6M shares, plus a future milestone payment Neuro-Biotech Corp. (Basel, Switzerland) Auric Pharma Science (Madrid, Spain) 2/11 4/5 ND Neuro-Biotech received an unsolicited offer to purchase all outstanding shares at 15 cents per share

Regeneron and partner Sanofi-Aventis will waste no time preparing marketing approval applications for the FDA and European Medicines Agency for submission in the second half of 2011

Earlier this month, Genzyme Corp., now a subsidiary of Paris-based Sanofi-Aventis Group, reported positive Phase III data for the antisense oligonucleotide, mipomersen, in HeFH

Ltd., Johnson & Johnson, Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc and Sanofi-Aventis Group

The current SciClone and NovaMed sales organizations in China will continue to operate separately under NovaMed CEO and co-founder Mark Lotter, who since helping start the company in August 2005 to provide "one-stop service" for companies looking to penetrate the China market, established exclusive licensing and promotion agreements with companies like Sanofi-aventis, Pfizer Inc

Zealand Pharma A/S, of Copenhagen, Denmark, and Sanofi-Aventis S/A, of Paris, reported top-line results from the GetGoal-S Phase III trial of lixisenatide in Type II diabetes showing the drug achieved its primary efficacy endpoint of significant HbA1c reduction, improving glycemic control from baseline as compared to placebo, and causing a reduction in body weight

The current SciClone and NovaMed sales organizations in China will continue to operate separately under NovaMed CEO and co-founder Mark Lotter, who since helping start the company in August 2005 to provide "one-stop service" for companies looking to penetrate the China market, established exclusive licensing and promotion agreements with companies like Sanofi-aventis, Pfizer Inc

Sanofi-Aventis SA (Paris) VEGF-Trap Aflibercept Non-small-cell lung cancer Failed to improve overall survival in a Phase III trial (3/14) Stemline Therapeutics Inc. (New York) SL-401 A cancer stem cell-targeting agent Acute myeloid leukemia FDA granted orphan drug designation (3/10) CARDIOVASCULAR United Therapeutics Corp. (Silver Spring, Md.) UT-15C Sustained-release oral formulation of treprostinil diethanolamine Pulmonary arterial hypertension Completed enrollment

Paris-based Sanofi-Aventis SA has joined forces with Harvard University on a research collaboration in areas such as cancer, diabetes and inflammation, and recently signed a new deal with Columbia University focused on diabetes

That program is partnered with Paris-based Sanofi-Aventis SA

Sanofi-Aventis pledged $60 million up front, with a potential $470 million in milestones...In July 2010, Merrimack and Sanofi-Aventis dosed the first patient in a Phase II study of MM-121 with Aromasin (exemestane) in breast cancer

Genzyme Corp., of Cambridge, Mass., a subsidiary of Sanofi-Aventis Group, reported additional five-year data from its Phase II multiple sclerosis trial showing that nearly two-thirds of alemtuzumab-treated patients remained free of clinically active disease as much as four years after most patients received their last course of treatment

Ltd., of Osaka, Japan, and with Paris-based Sanofi Aventis Group and its vaccines arm Sanofi Pasteur

Zealand Pharma A/S, of Copenhagen, and Sanofi-Aventis S/A, of Paris, reported top-line results from the GetGoal-S Phase III trial of lixisenatide in Type II diabetes showing the drug achieved its primary efficacy endpoint of significant HbA1c reduction, improving glycemic control from baseline as compared to placebo, and causing a reduction in body weight

Ltd., of Osaka, Japan, and with Paris-based Sanofi Aventis Group and its vaccines arm Sanofi Pasteur

Ltd., of Osaka, Japan, and with Paris-based Sanofi Aventis Group and its vaccines arm Sanofi Pasteur